FHL-601

FHL-601 is a preclinical **small molecule** candidate from **Forest Hills Business Association** being developed for **Parkinson's disease**. Based on the company's pipeline materials, FHL-601 is being advanced through a **refocused drug** regulatory pathway, indicating it is a **repurposed compound** rather than a newly disclosed chemical entity. Its precise molecular target and detailed mechanism have not been publicly disclosed, but available preclinical descriptions indicate **neuronal protection**, **lysosomal biogenesis-mediated clearance of pathogenic molecules**, and **attenuation of brain inflammation**, supporting a neuroprotective disease-modifying strategy in Parkinson's disease.